z-logo
Premium
Characterization of a Manganese‐Containing Nanoparticle as an MRI Contrast Agent
Author(s) -
Gianolio Eliana,
Bäckström Sania,
Petoral Rodrigo M.,
Olsson Anders,
Aime Silvio,
Axelsson Oskar
Publication year - 2019
Publication title -
european journal of inorganic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.667
H-Index - 136
eISSN - 1099-0682
pISSN - 1434-1948
DOI - 10.1002/ejic.201801472
Subject(s) - chemistry , nanoparticle , manganese , gadolinium , mri contrast agent , molecule , chelation , nuclear magnetic resonance , paramagnetism , analytical chemistry (journal) , nuclear chemistry , inorganic chemistry , nanotechnology , chromatography , organic chemistry , materials science , physics , quantum mechanics
We present relaxivity and physicochemical data for a high relaxivity, manganese‐containing, nanoparticle‐based, and tumor selective MRI contrast agent, SN132D. The nanoparticles have a diameter of 5–6 nm, selected to give a compromise between renal excretion and tumor contrast, based on the Enhanced Permeability and Retention effect. The per manganese relaxivity (r 1 ) is 24.8 ± 0.2 m m –1 Mn s –1 at 1.5 T and 37 °C in water, corresponding to per nanoparticle relaxivity of 347 ± 3 m m –1  s –1 . The NMRD profiles in both water and serum showed a peak in r 1 in the frequency range 20–40 MHz, which is characteristic of slowly moving paramagnetic systems. The r 1 decreases when the temperature is increased from 25 °C to 37 °C, indicating fast exchange dynamics of the coordinated water molecules. The exchange time constant of the whole water molecule, τ M O , was 6 ns. The r 1 in serum is significantly higher than in water, due to an increase in medium viscosity and chelation of 18.9 ± 2.0 % of Mn II ions to human serum components, most likely human serum albumin. The r 1 is stable in the pH range 3–10. The per Mn relaxivity is among the highest reported for Mn‐containing systems and far higher than those of the clinically used gadolinium‐based contrast agents.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here